More than 90% of pancreatic cancer cases are attributed to an aggressive, deadly form of the disease called pancreatic ductal adenocarcinoma, or PDAC. Rese...
Over the last few years, City of Hope has made significant strides in enhancing patient care through their dedicated focus on precision medicine. In an eff...
Key apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite* AI applications streamline workflow and s...
Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cance...
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment Fundraise led by Sofin...
Claritas, a leader in image enhancement and AI diagnostic solutions has developed pioneering technology for real-time precision detection of conditions in ...
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research coll...
The International Myeloma Foundation (IMF), which leads the Coalition to Improve Access to Cancer Care (CIACC), fervently supports the Cancer Drug Parity A...
“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...
– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...
The intellectual property was originally developed through a collaboration of Shuttle Pharma scientists with investigators from Georgetown University. The ...
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was ...
Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatm...
Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...
© 2025 Biopharma Boardroom. All Rights Reserved.
